ContextVision Future Growth
Future criteria checks 3/6
ContextVision is forecast to grow earnings and revenue by 41.2% and 1.8% per annum respectively. EPS is expected to grow by 42.4% per annum. Return on equity is forecast to be 12.7% in 3 years.
Key information
41.2%
Earnings growth rate
42.41%
EPS growth rate
| Healthcare Services earnings growth | 25.4% |
| Revenue growth rate | 1.8% |
| Future return on equity | 12.65% |
| Analyst coverage | Low |
| Last updated | 25 Feb 2026 |
Recent future growth updates
Analysis Article • Nov 09
ContextVision AB (publ) (OB:CONTX) Just Reported, And Analysts Assigned A kr5.00 Price Target
It's been a mediocre week for ContextVision AB (publ) ( OB:CONTX ) shareholders, with the stock dropping 11% to kr3.84...Analysis Article • Aug 30
Earnings Release: Here's Why Analysts Cut Their ContextVision AB (publ) (OB:CONTX) Price Target To kr5.00
ContextVision AB (publ) ( OB:CONTX ) shareholders are probably feeling a little disappointed, since its shares fell...Recent updates
Narrative Update • Apr 28
CONTX: Liver Biomarker Collaboration Will Sustain Overvaluation Risk For Ultrasound AI
Analysts have adjusted their price targets on ContextVision to reflect updated assumptions on revenue growth, profit margins and future P/E. The new target is now set at NOK X.XX, compared with the previous NOK Y.YY.Narrative Update • Apr 12
CONTX: Liver Biomarker Collaboration Will Support Fair Outlook For Ultrasound AI
Analysts have adjusted their price target on ContextVision to reflect updated assumptions for the discount rate, revenue growth, profit margin and future P/E. The implied fair value estimate now stands at NOK 3.30.Narrative Update • Mar 28
CONTX: Liver Study And Data Quality Program Will Support Fair Future Prospects
Analysts have adjusted their price target for ContextVision to align with a fair value estimate of NOK 3.30 per share, citing slightly updated assumptions for the discount rate and future P/E ratio, while keeping revenue growth and profit margin expectations broadly unchanged. Valuation Changes Fair Value: NOK 3.30 per share remains unchanged in the updated assessment.Narrative Update • Mar 11
CONTX: Liver Study And Data Quality Program Will Support Balanced Future Prospects
Analysts have reduced their fair value estimate for ContextVision from NOK 4.0 to NOK 3.3, citing updated assumptions for revenue growth, profit margins, future P/E levels, and a slightly higher discount rate. Valuation Changes Fair Value: Reduced from NOK 4.0 to NOK 3.3 per share, a modest cut in the equity valuation used in the model.Narrative Update • Feb 24
CONTX: Liver Study And Data Quality Program Will Support Stronger Future Upside
Analysts have raised their price target for ContextVision, citing slightly stronger assumptions on revenue growth, a marginally lower discount rate and a modestly higher future P/E. They have kept fair value and long-term profit margin expectations broadly in line with prior estimates, which together support a higher NOK-based valuation range.Narrative Update • Feb 09
CONTX: Liver Diagnostics Study Progress Will Support Steady Long Term Outlook
Analysts have adjusted their price target for ContextVision to reflect a fair value of $4.00 and a future P/E of 11.34, citing updated assumptions around discount rates and profitability. What's in the News ContextVision started patient enrollment in its clinical development program for liver disease diagnostics at the University of Washington in Seattle, following Institutional Review Board approval and completion of technical setup (Key Developments).Narrative Update • Jan 25
CONTX: Liver Study Progress And Buybacks Will Support Steady Long Term Outlook
Analysts have nudged their price target on ContextVision slightly higher to reflect small updates to fair value, discount rate, revenue growth, profit margin and future P/E assumptions, while keeping their overall outlook broadly unchanged. What's in the News ContextVision started the clinical phase of its liver disease diagnostics program at the University of Washington in Seattle, with the first patient first visit completed following Institutional Review Board approval and technical validation (Key Developments).Narrative Update • Jan 10
CONTX: Share Buybacks And Stable Assumptions Will Support Steady Long Term Outlook
Analysts have slightly adjusted their price target on ContextVision, reflecting modest tweaks to fair value, discount rate, revenue growth, profit margin and future P/E assumptions. They describe the move as a fine tuning of their outlook rather than a major shift in thesis.Narrative Update • Dec 25
CONTX: Share Buybacks Will Support Per Share Metrics With Stable Long Term Outlook
Analysts have nudged their price target on ContextVision slightly higher to reflect modest improvements in long term fair value and profitability assumptions, now estimating the stock to be worth approximately SEK 4.00 per share versus about SEK 4.00 previously. What's in the News Completed a share buyback tranche, repurchasing 1,440,211 shares (equivalent to 1.86% of outstanding capital) between September 5 and September 30, 2025 (Key Developments) Total consideration for the completed buyback program amounted to NOK 6.42 million under the mandate announced on September 15, 2025 (Key Developments) The conclusion of this buyback tranche reduces the free float and may provide incremental support to per share metrics ahead of future results updates (Key Developments) Valuation Changes Fair Value Estimate is effectively unchanged at around SEK 4.00 per share, reflecting only immaterial rounding differences in the model.Narrative Update • Dec 11
CONTX: Share Buybacks Will Support Capital Efficiency With Balanced Long Term Outlook
Analysts have raised their price target for ContextVision slightly, now valuing the shares at roughly SEK 4.00. This reflects modestly higher confidence in the companys long term earnings power, even as underlying model assumptions have changed only marginally.Narrative Update • Nov 27
CONTX: Share Repurchase Program Will Drive Capital Efficiency And Future Upside
Analysts have adjusted their price target for ContextVision slightly upward to $4.00, citing marginal updates to the discount rate as well as modest changes in growth and profitability assumptions. What's in the News ContextVision completed the repurchase of 1,440,211 shares, representing 1.86% of shares, for NOK 6.42 million between September 5 and September 30, 2025.Analysis Article • Nov 19
More Unpleasant Surprises Could Be In Store For ContextVision AB (publ)'s (OB:CONTX) Shares After Tumbling 25%
The ContextVision AB (publ) ( OB:CONTX ) share price has fared very poorly over the last month, falling by a...Narrative Update • Nov 12
CONTX: Share Repurchase Program And Margin Outlook Will Shape Future Performance
Analysts have lowered their price target for ContextVision from $5.00 to $4.00, citing a modest decline in expected revenue growth and a slightly higher discount rate. This adjustment comes despite improved profit margin forecasts.Analysis Article • Nov 09
ContextVision AB (publ) (OB:CONTX) Just Reported, And Analysts Assigned A kr5.00 Price Target
It's been a mediocre week for ContextVision AB (publ) ( OB:CONTX ) shareholders, with the stock dropping 11% to kr3.84...Analysis Article • Sep 09
We Think That There Are More Issues For ContextVision (OB:CONTX) Than Just Sluggish Earnings
A lackluster earnings announcement from ContextVision AB (publ) ( OB:CONTX ) last week didn't sink the stock price...Analysis Article • Aug 30
Earnings Release: Here's Why Analysts Cut Their ContextVision AB (publ) (OB:CONTX) Price Target To kr5.00
ContextVision AB (publ) ( OB:CONTX ) shareholders are probably feeling a little disappointed, since its shares fell...Narrative Update • Aug 09
Future Investments In POCUS And Asian Expansion Will Strengthen Market Presence
The downward revision in ContextVision's price target reflects a notable reduction in expected revenue growth, only partially offset by a modest improvement in profit margins, resulting in a lower fair value estimate of NOK5.00. What's in the News ContextVision entered a research partnership with AMRA Medical to advance AI-powered imaging solutions for metabolic dysfunction-associated steatotic liver disease (MASLD).Analysis Article • May 09
This Broker Just Slashed Their ContextVision AB (publ) (OB:CONTX) Earnings Forecasts
One thing we could say about the covering analyst on ContextVision AB (publ) ( OB:CONTX ) - they aren't optimistic...Analysis Article • Mar 04
There May Be Some Bright Spots In ContextVision's (OB:CONTX) Earnings
The market for ContextVision AB (publ)'s ( OB:CONTX ) shares didn't move much after it posted weak earnings recently...
New Narrative • Feb 26
Future Investments In POCUS And Asian Expansion Will Strengthen Market Presence
Expansion into Asian markets and integration with new customers will boost revenues via enhanced customer base and market presence.Analysis Article • Feb 25
Subdued Growth No Barrier To ContextVision AB (publ) (OB:CONTX) With Shares Advancing 25%
ContextVision AB (publ) ( OB:CONTX ) shares have had a really impressive month, gaining 25% after a shaky period...Analysis Article • Feb 15
Is Now An Opportune Moment To Examine ContextVision AB (publ) (OB:CONTX)?
While ContextVision AB (publ) ( OB:CONTX ) might not have the largest market cap around , it saw a significant share...Analysis Article • Sep 02
There May Be Some Bright Spots In ContextVision's (OB:CONTX) Earnings
Shareholders appeared unconcerned with ContextVision AB (publ)'s ( OB:CONTX ) lackluster earnings report last week. Our...Analysis Article • Mar 11
ContextVision AB (publ)'s (OB:CONTX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio
ContextVision AB (publ) ( OB:CONTX ) shares have had a horrible month, losing 26% after a relatively good period...Analysis Article • Feb 22
ContextVision's (OB:CONTX) Soft Earnings Are Actually Better Than They Appear
The most recent earnings report from ContextVision AB (publ) ( OB:CONTX ) was disappointing for shareholders. However...Analysis Article • Feb 18
ContextVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
It's been a mediocre week for ContextVision AB (publ) ( OB:CONTX ) shareholders, with the stock dropping 17% to kr7.50...Analysis Article • Jan 26
Earnings Not Telling The Story For ContextVision AB (publ) (OB:CONTX)
With a price-to-earnings (or "P/E") ratio of 18.4x ContextVision AB (publ) ( OB:CONTX ) may be sending very bearish...Analysis Article • Jun 22
When Should You Buy ContextVision AB (publ) (OB:CONTX)?
While ContextVision AB (publ) ( OB:CONTX ) might not be the most widely known stock at the moment, it saw a decent...Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 118 | 16 | 16 | 23 | 1 |
| 12/31/2027 | 116 | 12 | 12 | 19 | 1 |
| 12/31/2026 | 113 | 8 | 10 | 16 | 1 |
| 3/31/2026 | 113 | 5 | 5 | 8 | N/A |
| 12/31/2025 | 111 | 1 | 0 | 4 | N/A |
| 9/30/2025 | 109 | 4 | 2 | 9 | N/A |
| 6/30/2025 | 116 | 9 | 6 | 14 | N/A |
| 3/31/2025 | 120 | 13 | 19 | 26 | N/A |
| 12/31/2024 | 131 | 25 | 29 | 33 | N/A |
| 9/30/2024 | 135 | 22 | 30 | 30 | N/A |
| 6/30/2024 | 138 | 26 | 35 | 36 | N/A |
| 3/31/2024 | 138 | 33 | 42 | 43 | N/A |
| 12/31/2023 | 133 | 33 | 44 | 45 | N/A |
| 9/30/2023 | 135 | 37 | 40 | 44 | N/A |
| 6/30/2023 | 130 | 36 | 40 | 43 | N/A |
| 3/31/2023 | 128 | 36 | 36 | 40 | N/A |
| 12/31/2022 | 123 | 33 | 21 | 26 | N/A |
| 9/30/2022 | 117 | 34 | 18 | 25 | N/A |
| 6/30/2022 | 115 | 37 | 9 | 15 | N/A |
| 3/31/2022 | 106 | 35 | -4 | 2 | N/A |
| 12/31/2021 | 100 | 35 | 5 | 9 | N/A |
| 9/30/2021 | 94 | 53 | 8 | 8 | N/A |
| 6/30/2021 | 90 | 42 | 10 | 11 | N/A |
| 3/31/2021 | 86 | 35 | 18 | 23 | N/A |
| 12/31/2020 | 95 | 38 | 14 | 22 | N/A |
| 9/30/2020 | 99 | 8 | 11 | 23 | N/A |
| 6/30/2020 | 100 | 10 | 9 | 26 | N/A |
| 3/31/2020 | 103 | 13 | 0 | 20 | N/A |
| 12/31/2019 | 95 | 7 | N/A | 25 | N/A |
| 9/30/2019 | 95 | 14 | N/A | 22 | N/A |
| 6/30/2019 | 94 | 11 | N/A | 24 | N/A |
| 3/31/2019 | 93 | 5 | N/A | 11 | N/A |
| 12/31/2018 | 91 | -1 | N/A | 5 | N/A |
| 9/30/2018 | 85 | -2 | N/A | 5 | N/A |
| 6/30/2018 | 82 | -3 | N/A | 5 | N/A |
| 3/31/2018 | 82 | -2 | N/A | 4 | N/A |
| 12/31/2017 | 81 | -2 | N/A | 2 | N/A |
| 9/30/2017 | 83 | -1 | N/A | 5 | N/A |
| 6/30/2017 | 85 | 1 | N/A | 1 | N/A |
| 3/31/2017 | 81 | 0 | N/A | 4 | N/A |
| 12/31/2016 | 82 | 4 | N/A | 10 | N/A |
| 9/30/2016 | 76 | 3 | N/A | 6 | N/A |
| 6/30/2016 | 73 | 4 | N/A | 10 | N/A |
| 3/31/2016 | 72 | 5 | N/A | 12 | N/A |
| 12/31/2015 | 72 | 5 | N/A | 9 | N/A |
| 9/30/2015 | 70 | 5 | N/A | 9 | N/A |
| 6/30/2015 | 67 | 4 | N/A | 10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CONTX's forecast earnings growth (41.2% per year) is above the savings rate (3.3%).
Earnings vs Market: CONTX's earnings (41.2% per year) are forecast to grow faster than the Norwegian market (9.5% per year).
High Growth Earnings: CONTX's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CONTX's revenue (1.8% per year) is forecast to grow slower than the Norwegian market (2.1% per year).
High Growth Revenue: CONTX's revenue (1.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CONTX's Return on Equity is forecast to be low in 3 years time (12.7%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/22 22:50 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ContextVision AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Juste Subataviciute | Norne Securities AS |
| Christian Lee | Pareto Securities |
| Klas Palin | Redeye |